Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management.


Journal

JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 31 01 2019
revised: 14 03 2019
accepted: 27 09 2019
entrez: 20 3 2020
pubmed: 20 3 2020
medline: 20 3 2020
Statut: epublish

Résumé

We evaluated for the first time, to our knowledge, adverse health outcomes (AHOs) among US testicular cancer survivors (TCS) given chemotherapy (n = 381) vs surgery-only patients (n = 98) managed at a single institution, accounting for non-treatment-related risk factors to delineate chemotherapy's impact. Chemotherapy consisted largely of bleomycin-etoposide-cisplatin (BEP) administered in three or four cycles (BEPx3, n = 235; BEPx4, n = 82). Incidence of at least 3 AHOs was lowest in surgery-only TCS and increased with BEPx3, BEPx4, and other cisplatin-based regimens (12.2%, 40.8%, 52.5%, 54.8%;

Identifiants

pubmed: 32190815
doi: 10.1093/jncics/pkz079
pii: pkz079
pmc: PMC7065712
doi:

Types de publication

Journal Article

Langues

eng

Pagination

pkz079

Subventions

Organisme : NCI NIH HHS
ID : R01 CA157823
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press.

Références

Pain. 2014 Dec;155(12):2461-70
pubmed: 25261162
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70
pubmed: 23535024
Arthritis Rheum. 1999 Feb;42(2):306-10
pubmed: 10025925
J Clin Oncol. 2012 Jan 20;30(3):300-7
pubmed: 22184390
J Community Support Oncol. 2014 Apr;12(4):121-8
pubmed: 24971421
Med Oncol. 2007;24(2):175-81
pubmed: 17848741
Cancer. 2010 May 15;116(10):2322-31
pubmed: 20225230
Urology. 2007 Apr;69(4):748-53
pubmed: 17445663
Qual Life Res. 2011 Dec;20(10):1629-37
pubmed: 21499930
Ear Hear. 2003 Dec;24(6):501-7
pubmed: 14663349
Eur J Cancer. 1995 Dec;31A(13-14):2229-38
pubmed: 8652248
Lancet. 2004 Jun 26;363(9427):2151-61
pubmed: 15220040
J Clin Oncol. 2016 Aug 10;34(23):2712-20
pubmed: 27354478
Arch Otolaryngol Head Neck Surg. 1993 Feb;119(2):156-61
pubmed: 8427676
Heart. 2014 Dec;100(23):1837-43
pubmed: 25095826
Front Neurol. 2016 Oct 05;7:171
pubmed: 27761128
J Cancer Surviv. 2016 Dec;10(6):1051-1057
pubmed: 27169992
Ann Intern Med. 1977 Sep;87(3):293-8
pubmed: 71004
JAMA. 2015 Nov 24;314(20):2172-81
pubmed: 26599185
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Diabetes Care. 2011 Jul;34(7):1642-7
pubmed: 21593304
BMJ Open. 2015 Mar 16;5(3):e006389
pubmed: 25776043
J Clin Oncol. 2017 Apr 10;35(11):1211-1222
pubmed: 28240972
J Natl Cancer Inst. 2009 Dec 16;101(24):1682-95
pubmed: 19940282
BMJ Open. 2018 Feb 22;8(2):e016589
pubmed: 29472253
Int Arch Occup Environ Health. 2016 Apr;89(3):351-72
pubmed: 26249711
J Natl Compr Canc Netw. 2012 Apr;10(4):537-44
pubmed: 22491050

Auteurs

Vaibhav Agrawal (V)

Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.

Paul C Dinh (PC)

Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Department of Epidemiology and Biostatistics, Indiana University of Public Health, Bloomington, IN.

Chunkit Fung (C)

Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Division of Hematology and Oncology, Department of Medicine, University of Rochester School of Medicine and Dentistry, James P. Wilmot Cancer Institute, Rochester, NY.

Patrick O Monahan (PO)

Department of Biostatistics, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN.

Sandra K Althouse (SK)

Department of Biostatistics, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN.

Kelli Norton (K)

Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.

Clint Cary (C)

Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Department of Urology, Indiana University School of Medicine, Indianapolis, IN.

Lawrence Einhorn (L)

Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.

Sophie D Fossa (SD)

Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Department of Oncology, Oslo University Hospital, Radium Hospital, Oslo, Norway.

Nabil Adra (N)

Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.

Lois B Travis (LB)

Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.

Classifications MeSH